1-(1,3-Benzodioxol-5-ylcarbonyl)piperazine | 55966-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1-(1,3-Benzodioxol-5-ylcarbonyl)piperazine
• 英文别名: 1,3-benzodioxol-5-yl(piperazin-1-yl)methanone
• CAS: 55966-96-6
• 化学式: C₁₂H₁₄N₂O₃
• mdl: MFCD08444696
• 分子量: 234.255
• InChiKey: DSEWOOAOXQETRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基磺酰氟 、 1-(1,3-Benzodioxol-5-ylcarbonyl)piperazine 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以60%的产率得到benzo[1,3]dioxol-5-yl-(4-methanesulfonylpiperazin-1-yl)methanone
  参考文献：
  名称：

  在脂肪族磺酰胺平行合成中，磺酰氟替代磺酰氯

  摘要：

  在平行合成衍生自脂族胺的磺酰胺中，比较了两种类型的脂族磺酰卤（Cl与F）。脂肪族磺酰氟与带有额外官能团的胺显示出良好的效果，而相应的氯化物却不合格。两种磺酰基卤化物在与具有易于接近的氨基的胺的反应中都是有效的。脂肪族磺酰氯与带有空间位阻氨基的胺有效反应，而相应的氟化物显示低活性。

  DOI：

  10.1021/co400164z
• 作为产物：
  描述：

  胡椒酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 1-(1,3-Benzodioxol-5-ylcarbonyl)piperazine
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors

  摘要：

  We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to, or higher than AZD-2281. Among these compounds, 18q appeared to be the most notable one, which displayed an 8-fold improvement in enzymatic activity compared to AZD-2281. These efforts lay the foundation for our further investigation.

  DOI：

  10.1016/j.bmcl.2014.07.001

文献信息

• Antiallergic substance from Asarum sagittarioides and synthesis of some analogues.
  作者：SUMIO TERADA、TAKU MOTOMIYA、KIMITOMO YOSHIOKA、TOSHIHARU NARITA、SOSUKE YASUI、MUNEAKI TAKASE

  DOI：10.1248/cpb.35.2437

  日期：——

  The MeOH extract of Asarum sagittarioides (Aristolochiaceae) showed antihistaminic activity. N-Isobutyl-3, 4-methylenedioxybenzamide (1) was isolated as the active principle, and this compound was proved to be an antiallergic substance by pharmacological studies. Furthermore, in order to investigate the structure-activity relationships, some analogues of 1 were synthesized, and compounds 4 and 5 were found to show more potent activity than 1.

  箭根薯（马兜铃科）的甲醇提取物显示出抗组胺活性。从中分离得到活性成分N-异丁基-3,4-亚甲二氧基苯甲酰胺（1），并通过药理学研究证实该化合物具有抗过敏作用。此外，为了研究结构与活性的关系，合成了一系列1的类似物，其中化合物4和5被发现比1具有更强的活性。
• Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
  作者：Hongyu Qin、Jian Zhang、Yilu Zhao、Lihui Zhang、Jinhong Feng、Lei Zhang

  DOI：10.3389/fphar.2022.1054616

  日期：——

  Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers.Methods: Aiming to the discovery of olaparib analogs for the treatment of cancer, structural modifications were performed based on the

  简介：聚（ADP-核糖）聚合酶 (PARP) 抑制剂的开发已在癌症治疗中得到广泛研究。奥拉帕尼是第一个获批的 PARP 抑制剂，显示出抑制 BRCA（乳腺癌相关）突变和 BRCA 未突变癌症的效力。方法：为了发现用于治疗癌症的奥拉帕尼类似物，进行了基于奥拉帕尼的脚手架。在第一系列中，羰基还原为CH2个导致 PARP1 抑制活性降低。在保留原始羰基的情况下，通过引入酰肼和芳香族氮芥基团，衍生出具有强效 PARP1 抑制活性的分子。合成的化合物在 PARP1 酶抑制筛选、基于癌细胞的抗增殖测定、细胞周期停滞和细胞凋亡研究中进行了评估。的抗癌效力体外抗增殖试验。与奥拉帕尼和苯丁酸氮芥相比，分子 C2 在抑制多种 BRCA 未突变细胞系方面也表现出显着的效力。进一步分析揭示了 C2 在诱导 G2/M 期细胞周期停滞和促进细胞凋亡方面的作用。讨论：总的来说，奥拉帕尼-苯丁酸氮芥杂化分子 (C2) 可用作进一步药物设计的先导化合物。
• Novel Triazoles with Potent and Broad-Spectrum Antifungal Activity In Vitro and In Vivo
  作者：Panhu Zhu、Tao Zhou、Hong Chen、Xingru Chen、Xiaobing Wang、Lingyi Kong、Minghua Yang

  DOI：10.1021/acs.jmedchem.3c00266

  日期：2023.6.8

  and CYP51. To explore novel triazole antifungal agents, we synthesized three series of fluconazole-core compounds and focused on optimizing the chain based on molecule docking and in vitro results. The most potent S-F24 exhibited excellent broad-spectrum antifungal activity that was better or comparable to clinically used azoles. S-F24 maintained its potency even against multi-resistant Candida albicans

  三唑类药物在治疗真菌感染方面已显示出显着的功效。然而，越来越多的人担心耐药性的增加会对其有效性产生负面影响。通过设计精心设计的侧链，三唑类药物可以被赋予优势，例如更高的效力和克服耐药性的能力。这凸显了侧链和 CYP51 之间的多样化相互作用。为了探索新型三唑类抗真菌药物，我们合成了三个系列的氟康唑核心化合物，并根据分子对接和体外结果重点优化了链。最有效的S -F24表现出优异的广谱抗真菌活性，优于或可与临床使用的唑类药物相媲美。S -F24即使对抗多重耐药白色念珠菌也能保持其效力。此外，S -F24显示出良好的安全性，具有高选择性、低溶血效应和低诱导耐药性的倾向。我们的研究结果共同表明，在新型唑类药物的开发中，侧链修饰仍然具有很大的潜力。
• NOVEL QUINAZOLINE DERIVATIVES
  申请人：Japan Energy Corporation

  公开号：EP1229025A1

  公开（公告）日：2002-08-07

  Quinazoline derivatives represented by the general formula (1) or a pharmaceutically acceptable salt thereof in said formula R1 is nitro or halogen; R2 and R4 are each hydrogen, C1-4 alkyl, carboxyl, or C2-5 alkoxycarbonyl; R3 is hydrogen, amino, optionally substituted C1-4 alkyl, C1-4 alkanoyl, or C2-5 alkoxycarbonyl; W is carbon or nitrogen; and m is 0 to 2.

  通式（1）所代表的喹唑啉衍生物或其药学上可接受的盐，所述式中 R1 为硝基或卤素；R2 和 R4 分别为氢、C1-4 烷基、羧基或 C2-5 烷氧基羰基；R3 为氢、氨基、任选取代的 C1-4 烷基、C1-4 烷酰基或 C2-5 烷氧基羰基；W 为碳或氮；m 为 0 至 2。
• Synthesis and Antimycobacterial Evaluation of Novel Phthalazin-4-ylacetamides Against log- and Starved Phase Cultures
  作者：Dharmarajan Sriram、Perumal Yogeeswari、Palaniappan Senthilkumar、Dewakar Sangaraju、Rohit Nelli、Debjani Banerjee、Pritesh Bhat、Thimmappa H. Manjashetty

  DOI：10.1111/j.1747-0285.2010.00947.x

  日期：2010.4

  Twenty four novel 2‐[3‐(4‐bromo‐2‐fluorobenzyl)‐4‐oxo‐3,4‐dihydro‐1‐phthalazinyl]acetic acid amides were synthesized from phthalic anhydride and were subjected to in vitro and in vivo evaluation against log‐ and starved phase of mycobacterial species and Mycobacterium tuberculosis isocitrate lyase enzyme inhibition studies. Among the compounds screened, 2‐(2‐(4‐bromo‐2‐fluorobenzyl)‐1,2‐dihydro‐1‐oxophthalazin‐4‐yl)‐N‐(2,6‐dimethylphenyl)acetamide (5j) inhibited all eight mycobacterial species with MIC’s ranging from 0.08 to 5.05 μm and was non‐toxic to Vero cells till 126.43 μm. Four compounds were tested against starved culture of Mycobacterium tuberculosis and they inhibited with MIC’s ranging from 3.78 to 23.2 μm. Some compounds showed 40–66% inhibition against Mycobacterium tuberculosis isocitrate lyase enzyme at 10 μm. The docking studies also confirmed the binding potential of the compounds at the isocitrate lyase active site. In the in vivo animal model, 5j reduced the mycobacterial load in lung and spleen tissues with 1.38 and 2.9‐log10 protections, respectively, at 25 mg/kg body weight dose.